Skip to main content

Pediatric Pharmacology for the Primary Care Provider: Advances and Limitations.

Publication ,  Journal Article
Thompson, EJ; Wood, CT; Hornik, CP
Published in: Pediatrics
July 1, 2024

Despite >1 in 5 children taking prescription drugs in the United States, off-label drug use is common. To increase the study of drugs in children, regulatory bodies have enacted legislation to incentivize and require pediatric drug studies. As a result of this legislation, novel trial approaches, and an increase in personnel with pediatric expertise, there have been numerous advancements in pediatric drug development. With this review, we aim to highlight developments in pediatric pharmacology over the past 6 years for the most common disease processes that may be treated pharmacologically by the pediatric primary care provider. Using information extracted from label changes between 2018 and 2023, the published literature, and Clinicaltrials.gov, we discuss advances across multiple therapeutic areas relevant to the pediatric primary care provider, including asthma, obesity and related disorders, mental health disorders, infections, and dermatologic conditions. We highlight instances in which new drugs have been developed on the basis of a deeper mechanistic understanding of illness and instances in which labels have been expanded in older drugs on the basis of newly available data. We then consider additional factors that affect pediatric drug use, including cost and nonpharmacologic therapies. Although there is work to be done, efforts focused on pediatric-specific drug development will increase the availability of evidence-based, labeled guidance for commonly prescribed drugs and improve outcomes through the safe and effective use of drugs in children.

Duke Scholars

Published In

Pediatrics

DOI

EISSN

1098-4275

Publication Date

July 1, 2024

Volume

154

Issue

1

Location

United States

Related Subject Headings

  • United States
  • Primary Health Care
  • Pediatrics
  • Pediatrics
  • Off-Label Use
  • Humans
  • Drug Development
  • Child
  • Asthma
  • 52 Psychology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Thompson, E. J., Wood, C. T., & Hornik, C. P. (2024). Pediatric Pharmacology for the Primary Care Provider: Advances and Limitations. Pediatrics, 154(1). https://doi.org/10.1542/peds.2023-064158
Thompson, Elizabeth J., Charles T. Wood, and Christoph P. Hornik. “Pediatric Pharmacology for the Primary Care Provider: Advances and Limitations.Pediatrics 154, no. 1 (July 1, 2024). https://doi.org/10.1542/peds.2023-064158.
Thompson EJ, Wood CT, Hornik CP. Pediatric Pharmacology for the Primary Care Provider: Advances and Limitations. Pediatrics. 2024 Jul 1;154(1).
Thompson, Elizabeth J., et al. “Pediatric Pharmacology for the Primary Care Provider: Advances and Limitations.Pediatrics, vol. 154, no. 1, July 2024. Pubmed, doi:10.1542/peds.2023-064158.
Thompson EJ, Wood CT, Hornik CP. Pediatric Pharmacology for the Primary Care Provider: Advances and Limitations. Pediatrics. 2024 Jul 1;154(1).

Published In

Pediatrics

DOI

EISSN

1098-4275

Publication Date

July 1, 2024

Volume

154

Issue

1

Location

United States

Related Subject Headings

  • United States
  • Primary Health Care
  • Pediatrics
  • Pediatrics
  • Off-Label Use
  • Humans
  • Drug Development
  • Child
  • Asthma
  • 52 Psychology